Free shipping on orders over $149
SafeRxPills - Online Pharmacy
These products are intended for personal use only. We are not licensed by the FDA.
Back to BlogEye Care

Glaucoma Eye Drops: Every Type Compared, How Well Each Works, Side Effects and Cap Colors

S

SafeRxPills Pharmacy Team

Editorial team at SafeRxPills. Articles are written and checked against regulatory drug labelling (DailyMed, FDA, EMA) and published literature.

July 7, 202628 min read
Last updated: October 29, 2026
Share:
In this article (25 sections)

Glaucoma eye drops lower the pressure inside the eye (intraocular pressure, or IOP), the main risk factor for glaucoma damage that treatment can change. The Vyzulta label calls it "a major modifiable risk factor for glaucoma progression." There are six main types of drop: prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, the rho kinase inhibitor netarsudil, and the older miotic pilocarpine. Fixed combination bottles put two of these in one drop. The American Academy of Ophthalmology (AAO) says prostaglandin analogs are often chosen first, because they lower pressure the most, are well tolerated and are used once a day.

This guide compares the types side by side: how much each lowers pressure, how often it is used, who should not use it according to the US label, the side effects each class is known for, the cap color code, and how to put the drops in. Two drugs have their own detailed guides, so here they get a short summary: latanoprost eye drops and Lumigan (bimatoprost) for glaucoma. We sell several of the drops discussed, so we have a commercial interest. Every number below comes from the sources listed at the end, opened on 29 October 2026. This page is general information, not a substitute for your eye doctor, who chooses the drug based on your pressure, your eyes and your general health.

Glaucoma eye drops at a glance

TypeExamples (US brand)How it lowers pressureDoses a dayExpected IOP drop (AAO)
Prostaglandin analogsLatanoprost (Xalatan), bimatoprost (Lumigan), travoprost (Travatan Z), tafluprost (Zioptan), latanoprostene bunod (Vyzulta)More fluid drains out of the eye1, in the evening25% to 33%
Beta blockersTimolol (Timoptic, Istalol), betaxolol (Betoptic S)Less fluid is made1 to 220% to 25%
Alpha 2 agonistsBrimonidine (Alphagan P)Less fluid made, more drainage320% to 25%
Carbonic anhydrase inhibitorsDorzolamide, brinzolamide (Azopt)Less fluid is made315% to 20%
Rho kinase inhibitorNetarsudil (Rhopressa)More drainage through the trabecular meshwork1, in the evening10% to 20%
MioticPilocarpineMore drainage through the trabecular meshworkVaries20% to 25%
Fixed combinationsCosopt, Combigan, Simbrinza, RocklatanTwo mechanisms in one bottle1 to 3About 1 to 3 mmHg more than either drug alone (labels)

Expected IOP drop ranges are from Table 4 of the AAO Primary Open-Angle Glaucoma Preferred Practice Pattern (approved 6 September 2025). Dosing is from section 2 of each US label.

How glaucoma eye drops work

The front of the eye is filled with a clear fluid called aqueous humor. It is made constantly by the ciliary body and drains out mainly through the trabecular meshwork in the angle of the eye, with a second route (uveoscleral outflow) through the tissue around it. Eye pressure depends on the balance between how much fluid is made and how easily it leaves.

Every glaucoma drop works on one side of that balance or both. Beta blockers and carbonic anhydrase inhibitors reduce how much fluid is made. Prostaglandin analogs increase uveoscleral outflow. Netarsudil, according to its label, is believed to increase outflow through the trabecular meshwork. Brimonidine works on both sides: the AAO table lists decreased fluid production, plus decreased episcleral venous pressure or increased uveoscleral outflow. Because the mechanisms are different, two drugs from different classes add to each other, which is why combination bottles exist. Two drugs from the same class do not add much, and two beta blockers or two prostaglandins together are specifically not recommended on the labels.

Lowering pressure does not undo damage already done to the optic nerve; the aim is to slow further loss. The AAO guideline summarizes the major clinical trials in which lowering IOP slowed glaucoma progression. Our glaucoma condition page explains the disease itself.

Which glaucoma eye drop is usually tried first

The AAO Preferred Practice Pattern (PPP) is the main US guideline for open-angle glaucoma. Its wording on first choice is: "Prostaglandin analogs are the most frequently prescribed eye drops for lowering IOP in patients with glaucoma because they are most efficacious and well tolerated, and they need to be instilled only once daily." It continues that prostaglandin analogs "are often selected as initial medical therapy unless other considerations, such as contraindications, cost, side effects, intolerance, or patient refusal preclude this."

Drops are not the only first step. The same guideline describes trials that compared eye drops with selective laser trabeculoplasty (SLT) as first treatment and says recent data "further support its use as an initial therapy." So a newly diagnosed patient may be offered a laser instead of, or as well as, drops.

If one drug does not lower pressure enough, the guideline says switching to another drug or adding a second one are both reasonable. It notes that fixed combinations may help adherence and reduce preservative exposure, "although it is not recommended for initial treatment in most circumstances." Each extra drug tends to add less than the first: in one analysis the guideline cites, the first medication lowered IOP by 24% and each additional drop added about 4%.

How much each type lowers eye pressure

The best single source that puts the common drops on the same scale is a meta-analysis of 28 randomized trials with about 6,900 patients with open-angle glaucoma or ocular hypertension (van der Valk and colleagues, Ophthalmology 2005). It pooled the IOP drop from baseline after one month at the peak of each drug's effect and at trough, just before the next dose. Trough matters because it is the weakest point of the day, when the drop is wearing off.

DrugPeak IOP reductionTrough IOP reduction
Bimatoprost 0.03%33%28%
Latanoprost 0.005%31%28%
Travoprost 0.004%31%29%
Timolol 0.5%27%26%
Brimonidine 0.2%25%18%
Betaxolol 0.5%23%20%
Dorzolamide 2%22%17%
Brinzolamide 1%17%17%
Placebo5%5%
Grouped bar chart of pooled eye pressure reduction from baseline at 1 month, peak and trough: bimatoprost 0.03% 33% and 28%, latanoprost 0.005% 31% and 28%, travoprost 0.004% 31% and 29%, timolol 0.5% 27% and 26%, brimonidine 0.2% 25% and 18%, betaxolol 0.5% 23% and 20%, dorzolamide 2% 22% and 17%, brinzolamide 1% 17% and 17%, placebo 5% and 5%.
Figure 1. How much each common glaucoma drop lowered eye pressure at its peak effect and at trough, pooled across randomized trials. Source: van der Valk 2005 meta-analysis, PMID 15921747.

The authors concluded that bimatoprost, travoprost, latanoprost and timolol were the most effective. Brimonidine shows the widest gap between peak (25%) and trough (18%), and dorzolamide also drops off (22% to 17%), which fits with both being used three times a day. The gap between timolol and the prostaglandins in absolute terms was small: 1.0 to 1.5 mmHg at peak and essentially none at trough (minus 0.4 to plus 0.1 mmHg). The study predates netarsudil and latanoprostene bunod, which are covered from their own labels below.

What the AAO guideline expects from each class

The 2025 AAO guideline gives an expected range for each class rather than single numbers. These ranges come from the European Glaucoma Society guidelines, which the AAO table cites.

Drug classExpected IOP reductionPotential contraindications listed by the AAO
Prostaglandin analogs25% to 33%Macular edema, history of herpetic keratitis, active uveitis
Beta blockers20% to 25%COPD, asthma, heart failure, bradycardia, hypotension, heart block greater than first degree
Alpha 2 agonists20% to 25%MAO inhibitor therapy, infants and children
Pilocarpine (miotic)20% to 25%Areas of peripheral retina that predispose to breaks; neovascular, uveitic or malignant glaucoma
Topical carbonic anhydrase inhibitors15% to 20%Sulfonamide allergy, sickle cell disease with hyphema
Rho kinase inhibitor (netarsudil)10% to 20%None listed
Grouped bar chart of expected eye pressure reduction by drug class from the AAO 2025 guideline: prostaglandin analogs 25% to 33%, beta blockers 20% to 25%, alpha 2 agonists 20% to 25%, pilocarpine 20% to 25%, carbonic anhydrase inhibitor drops 15% to 20%, rho kinase inhibitor netarsudil 10% to 20%.
Figure 2. Expected pressure lowering for each class of glaucoma drop, as a range. Source: AAO Primary Open-Angle Glaucoma Preferred Practice Pattern, Table 4.

These are the guideline's "potential" contraindications, a broader list than the formal contraindications on each US label. The label wording for each drug is in the sections that follow.

Prostaglandin analogs

This class includes latanoprost 0.005%, bimatoprost 0.01% and 0.03%, travoprost 0.004%, tafluprost 0.0015% and latanoprostene bunod 0.024%. They are all used as one drop in the evening, and the labels warn against using them more often: the Xalatan label says more than once daily "may decrease the IOP lowering effect or cause paradoxical elevations in IOP," and that combining two or more prostaglandins is not recommended.

What the US labels report in their own trials:

Drug (US brand)Baseline IOP in the trialsIOP reduction reported
Latanoprost 0.005% (Xalatan)24 to 25 mmHg6 to 8 mmHg at 6 months, equivalent to timolol 0.5% twice daily
Bimatoprost 0.01% (Lumigan)23.5 mmHgUp to 7.5 mmHg over 12 months
Travoprost 0.004% (Travatan Z)25 to 27 mmHg7 to 8 mmHg
Tafluprost 0.0015% (Zioptan)23 to 26 mmHg6 to 8 mmHg at 3 months, 5 to 8 mmHg at 6 months
Latanoprostene bunod 0.024% (Vyzulta)26.7 mmHgUp to 7 to 9 mmHg

The class shares a set of eye changes that patients should know about before starting. The labels describe increased brown pigmentation of the iris, darkening of the eyelid skin and eyelashes, and longer, thicker eyelashes. The Xalatan and Lumigan labels say that after stopping, "pigmentation of the iris is likely to be permanent," while eyelid and lash changes have been reported to reverse in some patients. The labels also carry warnings on intraocular inflammation, macular edema and herpetic keratitis, which match the AAO's potential contraindications. The Travatan Z, Zioptan and Vyzulta labels list no contraindications; Xalatan and Lumigan list only hypersensitivity to the ingredients.

Latanoprost in brief

Latanoprost 0.005% is one drop in the evening. In the Xalatan label trials, eye redness (conjunctival hyperemia) was reported in 8% of latanoprost patients against 3% on timolol, and increased iris pigmentation in 7% against 0%. Fewer than 1% stopped because of redness. The Xalatan label says to store unopened bottles in the refrigerator at 2 to 8 °C, and once opened a bottle may be kept at room temperature up to 25 °C for 6 weeks. Dosing, preservative free versions, side effect tables and the iris color question are covered in our latanoprost eye drops guide.

Bimatoprost (Lumigan) in brief

Bimatoprost comes as 0.01% and 0.03%; the current US Lumigan label we used is for 0.01%. In the 12 month Lumigan 0.01% study, the most common adverse reaction was conjunctival hyperemia in 31% of patients, and about 1.6% stopped because of it. Bimatoprost 0.03% had the largest peak effect (33%) in the meta-analysis above; that study did not include the 0.01% strength. Strengths, side effects and cost are in our Lumigan glaucoma guide, and the difference between Lumigan and the Indian brand Careprost is explained in Lumigan vs Careprost.

Latanoprostene bunod (Vyzulta)

Latanoprostene bunod 0.024% is a newer prostaglandin. It is rapidly broken down into latanoprost and a nitric oxide donating part (AAO guideline); the Vyzulta label says this happens in the eye. The label also says it is thought to increase outflow through both the trabecular meshwork and the uveoscleral route. In 811 patients in two controlled trials of up to 12 months, the most common eye reactions were conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%) and instillation site pain (2%). About 0.6% stopped because of eye reactions. It is used once daily in the evening and has no listed contraindications.

Beta blockers: timolol and betaxolol

Beta blocker drops reduce the amount of fluid the eye makes. Timolol is nonselective, meaning it blocks both beta 1 receptors (mainly heart) and beta 2 receptors (mainly lungs). Betaxolol is cardioselective. The AAO guideline says betaxolol targets beta 1 receptors and so minimizes, "but do[es] not completely eliminate," the risk of lung side effects in people with obstructive airway disease.

Timolol 0.5% came close to the prostaglandins at trough in the meta-analysis above (26% against 28% to 29%). The Timoptic label starts with one drop of 0.25% twice daily, moves to 0.5% twice daily if needed, and allows once daily if pressure stays controlled. It says doses above one drop of 0.5% twice a day generally do not add more effect. The AAO guideline adds a practical point: beta blockers may be used once or twice daily, but night time dosing "is associated with limited efficacy" and may contribute to visual field progression through lower blood pressure at night. Betoptic S (betaxolol 0.25% suspension) is used twice daily and needs shaking.

The main local side effect on the Timoptic label is burning and stinging on instillation, in about one in eight patients. Because the drop is absorbed into the bloodstream, the label lists the same kinds of effects as beta blocker tablets, including slow heart rate, low blood pressure, bronchospasm, fatigue, depression and masked symptoms of low blood sugar.

Who should not use timolol drops

This is the most important safety point in glaucoma drops. The Timoptic label states: "TIMOPTIC is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product."

The warnings section explains why: "severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate." It adds that people with mild or moderate COPD or other bronchospastic disease "should, in general, not receive beta-blockers," and that beta blockers should be used with caution in diabetes because they can mask the signs of low blood sugar.

The same contraindications appear on every combination that contains timolol: the US Cosopt and Combigan labels, and the EU product information for travoprost with timolol (DuoTrav) and bimatoprost with timolol (Ganfort). For betaxolol, the Betoptic S label lists sinus bradycardia, heart block greater than first degree, cardiogenic shock, overt cardiac failure and hypersensitivity as contraindications. Asthma is not on that list, but the label warns that "There have been reports of asthmatic attacks and pulmonary distress during betaxolol treatment." Tell your eye doctor about any breathing or heart problem before starting any beta blocker drop.

Alpha agonists: brimonidine

Brimonidine comes as 0.1% and 0.15% (Alphagan P) and as generic 0.2%. The US labels give one drop three times daily, about 8 hours apart. The Alphagan P label says 0.15% is comparable to and 0.1% is equivalent to brimonidine 0.2% in IOP lowering, at approximately 2 to 6 mmHg. In the meta-analysis, brimonidine 0.2% lowered pressure by 25% at peak but 18% at trough, the biggest peak to trough gap of the drugs studied.

The labelled contraindication that matters most is age. The Alphagan P label states: "ALPHAGAN P is contraindicated in neonates and infants (pediatric patients younger than 2 years old)." It reports apnea, bradycardia, coma, hypotension, hypothermia, lethargy, respiratory depression and somnolence in infants after marketing. In a study of children aged 2 to 7, somnolence occurred in 50% to 83% of those aged 2 to 6. The label also advises caution in severe cardiovascular disease, depression, cerebral or coronary insufficiency and Raynaud's phenomenon, and notes that MAO inhibitors may theoretically raise side effects such as low blood pressure.

In adults, the label's most frequent reactions (about 10% to 20%) were allergic conjunctivitis, eye redness and itching. Dry mouth, burning and conjunctival follicles were reported in about 5% to 9%.

Carbonic anhydrase inhibitors: dorzolamide and brinzolamide

Dorzolamide 2% (first sold as Trusopt; a DailyMed search for Trusopt returned no label on 29 October 2026, so we used a generic dorzolamide label) and brinzolamide 1% (Azopt) reduce fluid production by blocking the enzyme carbonic anhydrase in the ciliary body. Both labels give one drop three times daily. Dorzolamide lowered IOP by about 3 to 5 mmHg in its label studies, and Azopt by 4 to 5 mmHg, equivalent to dorzolamide in the same studies. Azopt caused less stinging and burning than dorzolamide in two studies.

Both drugs are sulfonamides, and both labels carry the same warning. The dorzolamide label says it "contains dorzolamide, a sulfonamide; and although administered topically, it is absorbed systemically." It warns that "Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias," and that the drop should be stopped if signs of serious reactions or hypersensitivity occur. The formal US contraindication is hypersensitivity to any component; the AAO guideline lists sulfonamide allergy as a potential contraindication for the class. If you have had a reaction to a sulfa drug, say so before using either.

The typical complaints are local. With dorzolamide, about one third of patients had burning, stinging or discomfort right after the drop and about one quarter noticed a bitter taste. With Azopt, blurred vision and a bitter, sour or unusual taste were reported in 5% to 10%. Azopt is a suspension and needs shaking, and its label asks for at least 10 minutes between it and other drops.

Rho kinase inhibitor: netarsudil (Rhopressa)

Netarsudil 0.02% is the rho kinase inhibitor listed in the AAO guideline. Its label says it is believed to lower IOP by increasing outflow through the trabecular meshwork, and that the exact mechanism is unknown. It is used once daily in the evening; the label says twice a day "is not well tolerated and is not recommended."

Three trials showed reductions of up to 5 mmHg. For people starting below 25 mmHg, netarsudil once daily was similar to timolol 0.5% twice daily. At 25 mmHg or higher, it lowered morning pressure less than timolol, by as much as 3 mmHg. The AAO range for the class is 10% to 20%.

Eye redness is the defining side effect: conjunctival hyperemia in 53% of patients, and 6% stopped because of it. About 20% had corneal verticillata (fine deposits on the cornea, first seen at 4 weeks, without apparent effect on vision and mostly resolving after stopping), instillation site pain or small conjunctival bleeds. The label lists no contraindications.

Pilocarpine and older drops

Pilocarpine is a miotic: it constricts the pupil and pulls on the trabecular meshwork to open the drainage route. The AAO table gives it a 20% to 25% IOP reduction but also a long side effect list, including increased nearsightedness, decreased vision, eye or brow ache, cataract and retinal tears or detachment. The guideline still lists it among the drugs used for long term IOP reduction. In the Timoptic label trials, timolol twice daily lowered pressure more than pilocarpine 1% to 4% used four times a day. Oral carbonic anhydrase inhibitors such as acetazolamide also lower IOP (20% to 30% in the AAO table) but carry systemic risks and are not drops.

Fixed combination glaucoma drops

A combination bottle gives two drugs in one drop, which means fewer drops and fewer waits between them. The labels show a consistent pattern: the combination lowers pressure more than either drug alone, but slightly less than the two drugs given separately at their full dosing.

Combination (US or EU brand)DrugsDoses a dayWhat the label reports
CosoptDorzolamide 2% + timolol 0.5%21 to 3 mmHg more than either drug alone; about 1 mmHg less than both used separately
CombiganBrimonidine 0.2% + timolol 0.5%2, about 12 hours apart1 to 3 mmHg more than brimonidine and 1 to 2 mmHg more than timolol in the first 7 hours; about 1 to 2 mmHg less than both separately
SimbrinzaBrinzolamide 1% + brimonidine 0.2%31 to 3 mmHg more than either drug alone; no beta blocker
RocklatanNetarsudil 0.02% + latanoprost 0.005%1, in the evening1 to 3 mmHg more than either drug alone over 3 months
DuoTrav (EU)Travoprost 0.004% + timolol 0.5%1, same time each dayEU product; for people insufficiently responsive to a beta blocker or prostaglandin; timolol contraindications apply
Ganfort (EU)Bimatoprost 0.03% + timolol 0.5%1, same time each dayEU product; same indication wording as DuoTrav; timolol contraindications apply

Any combination inherits the warnings of both parts. Cosopt and Combigan are contraindicated in asthma, history of asthma, severe COPD, sinus bradycardia, second or third degree heart block, overt cardiac failure and cardiogenic shock. Combigan and Simbrinza are contraindicated under the age of 2 because of brimonidine. Cosopt and Simbrinza carry the sulfonamide warning. The labels describe Cosopt as indicated for people "insufficiently responsive to beta-blockers," and Combigan for patients who need adjunctive or replacement therapy, which matches the AAO view that combinations are mostly a second step.

Side effects by type of glaucoma drop

TypeWhat patients notice mostSystemic concerns on the label
Prostaglandin analogsRed eyes, longer darker lashes, darker iris (often permanent), darker eyelid skinFew; warnings are about the eye (inflammation, macular edema, herpes keratitis)
Beta blockersBurning or stinging (about 1 in 8 on timolol)Slow heart rate, bronchospasm, low blood pressure, fatigue, masked low blood sugar
BrimonidineAllergic conjunctivitis, red and itchy eyes (about 10% to 20%), dry mouthDrowsiness and breathing problems in infants and young children; caution in severe heart disease
Dorzolamide, brinzolamideStinging (about a third on dorzolamide), bitter taste, blurred vision after the dropSulfonamide reactions, rare but can be severe
NetarsudilRed eyes (53%), corneal deposits (about 20%), pain on instillationNone listed as contraindications

Eye redness is the side effect people ask about most, and the rate varies a lot between once daily drops in their own label trials. Among the prostaglandins, the highest figure is on the Travatan Z label, which reports it as a range:

DrugConjunctival hyperemia in label trialsStopped because of redness
Netarsudil 0.02%53%6%
Travoprost 0.004% (ocular hyperemia, Travatan and Travatan Z trials)30% to 50%Up to 3%
Bimatoprost 0.01%31%About 1.6%
Latanoprost 0.005%8% (timolol 3%)Fewer than 1%
Latanoprostene bunod 0.024%6%About 0.6% stopped for any eye reaction
Bar chart of eye redness (conjunctival or ocular hyperemia) rates in each US label's own trials: netarsudil 0.02% 53%, travoprost 0.004% 30% to 50% (a range, bar drawn to 50%), bimatoprost 0.01% 31%, latanoprost 0.005% 8%, latanoprostene bunod 0.024% 6%, and timolol 0.5% 3% as the comparator in the latanoprost trials. Separate trials, not head to head.
Figure 3. How often eye redness was reported with each drop in its own label trials, with timolol shown as the comparator from the latanoprost trials. The Travatan Z label gives a range of 30% to 50%. Six percent of netarsudil patients and up to 3% of travoprost patients stopped because of it. Sources: US prescribing information, section 6.1.

These come from separate trials with different designs, so they show the general pattern rather than a precise ranking. The Zioptan label reports conjunctival hyperemia in a range of 4% to 20% across its five studies.

How often each glaucoma drop is used

Adherence is a real problem in glaucoma. The AAO guideline cites a study in which nearly 45% of patients took fewer than 75% of their doses, even with free medication, once daily dosing, a dosing aid and electronic monitoring. Fewer doses a day makes the routine easier, which is one reason prostaglandins and once daily drugs are favored.

ProductLabel dosing
Latanoprost, bimatoprost, travoprost, tafluprost, latanoprostene bunodOne drop once daily in the evening
Netarsudil, RocklatanOne drop once daily in the evening
Timolol (Timoptic)One drop twice daily; once daily if pressure stays controlled
Betaxolol (Betoptic S)One drop twice daily, shake well
Cosopt, CombiganOne drop twice daily
Brimonidine 0.1%, 0.15%, 0.2%One drop three times daily, about 8 hours apart
Dorzolamide, brinzolamide (Azopt)One drop three times daily
SimbrinzaOne drop three times daily, shake well

If you miss a dose of a once daily evening drop, the Xalatan and Rhopressa labels say to continue with the next dose as normal. Do not double up: more than once daily can make prostaglandins work less well.

The glaucoma eye drop cap color code

In the US, glaucoma drop bottles follow a color code for caps and labels so patients can tell their drops apart. It comes from an AAO policy developed with input from the FDA and the pharmaceutical industry after reports of serious adverse events from patients mixing up their drops. The AAO describes it as voluntary cooperation and recommends that "No other topical medications should carry the same color." The glaucoma colors in the AAO policy (last revised June 2015) are:

ClassAAO cap colorWhat the US label we checked says
Prostaglandin analoguesTurquoiseTurquoise cap on Xalatan, Lumigan 0.01%, Vyzulta; turquoise overcap on Travatan Z
Beta blockersYellowYellow cap on Timoptic 0.25% and 0.5%
Beta blocker combinationsDark blueCosopt and Combigan contain a beta blocker
Adrenergic agonistsPurpleBrimonidine
Adrenergic agonist combinationsLight greenLight green cap on Simbrinza
Carbonic anhydrase inhibitorsOrangeOrange cap on the Sandoz dorzolamide label
MioticsDark greenPilocarpine
Rho kinase inhibitor (not in the AAO list)None assignedWhite cap on Rhopressa and on Rocklatan

Netarsudil is not in the AAO list, and its labels describe white caps, so a white cap does not tell you the class. Two cautions apply. First, the code is a voluntary recommendation, not a law. Second, packs made for other countries, including Indian brands, are not bound by the US system and may use different cap colors. Always read the drug name on the bottle rather than relying on the cap alone, especially if you use more than one drop.

How to put in glaucoma eye drops

The AAO patient guide gives these steps, summarized:

  1. Wash your hands. Take out contact lenses unless your doctor has told you otherwise. Shake the bottle if it is a suspension (Azopt, Betoptic S and Simbrinza say to shake well).
  2. Remove the cap without touching the dropper tip.
  3. Tilt your head back and look up. Pull the lower eyelid down to make a small pocket.
  4. Hold the tip over the pocket without touching the eye, lid or lashes, and squeeze gently so one drop falls in.
  5. Close your eyes and press gently on the inner corner, where the eyelid meets the nose, for a minute or two. This keeps the drop in the eye instead of draining into the nose.
  6. Wipe off any excess with a tissue, repeat for the other eye if prescribed, and wash your hands.

Step 5 matters for glaucoma drops in particular. The AAO guideline says patients should be taught eyelid closure or nasolacrimal occlusion "to reduce systemic absorption," and the Ganfort EU label says closing the eyelids for 2 minutes reduces systemic absorption, which may lower systemic side effects. This is most relevant for timolol and other beta blockers, whose labels describe heart and lung effects from the drug that is absorbed.

Never touch the tip to the eye. The labels warn that bacterial keratitis has been reported with contaminated multi dose bottles, and that serious damage and loss of vision may result.

Using more than one drop: the 5 minute rule

Most US glaucoma labels say that if more than one eye drop is used, they should be given at least 5 minutes apart. The AAO guideline lists "waiting at least 5 minutes between multiple drop regimens" as part of correct technique, and the AAO patient guide says 3 to 5 minutes. A second drop given straight away can wash the first one out.

Two labels ask for longer. Azopt says other drops should be given at least 10 minutes apart, and Betoptic S says to give other drops at least 10 minutes before it. If your regimen includes either, use 10 minutes. A combination bottle removes one of the waits, which is part of why doctors use them.

Contact lenses and preservatives

Many glaucoma drops contain the preservative benzalkonium chloride, which can be absorbed by soft contact lenses. The Xalatan, Timoptic and Betoptic S labels say to remove lenses before the drop and wait 15 minutes before putting them back. The Rhopressa label says the same.

People using several preserved drops for years can develop irritated, dry eyes. Preservative free versions exist for some drugs, including tafluprost (the Zioptan label describes preservative free single use containers), and among our products Lacoma PF and Dorzox PF are sold as preservative free. The AAO guideline notes that combinations can reduce preservative exposure. Dry eye from other causes is a separate problem, covered in our cyclosporine eye drops guide.

Glaucoma eye drops we stock and their prices

These are the glaucoma drops on our site, sourced as Indian market packs. Prices are from our store as of 29 October 2026, in US dollars, and can change. They are prescription medicines: use them only as your eye doctor prescribes, and do not start or switch a glaucoma drop without one.

ProductDrug and typeBottlePricePer bottle
Latoprost (Sun Pharma)Latanoprost 0.005%, prostaglandin2.5 mL1 for $24.00; 3 for $56.00; 6 for $100.00$24.00 to $16.67
Lacoma PF (Ajanta)Latanoprost, preservative free, prostaglandin2.5 mL1 for $18.00; 3 for $51.00; 6 for $100.00$18.00 to $16.67
Lumigan 0.01%Bimatoprost 0.01%, prostaglandin3 mL3 for $44.00; 6 for $76.00$14.67 to $12.67
Lumigan 0.03%Bimatoprost 0.03%, prostaglandin3 mL3 for $50.00; 6 for $90.00$16.67 to $15.00
Iobet (FDC)Betaxolol, beta blocker5 mL3 for $14.00; 6 for $25.00; 12 for $48.00$4.67 to $4.00
AlphaganBrimonidine 0.2%, alpha agonist5 mL3 for $36.00; 6 for $70.00; 12 for $137.50$12.00 to $11.46
Alphagan PBrimonidine 0.15%, alpha agonist5 mL1 for $18.00; 3 for $41.25; 6 for $80.00$18.00 to $13.33
Dorzox (Cipla)Dorzolamide 2%, carbonic anhydrase inhibitor5 mL1 for $16.00; 3 for $37.00; 6 for $67.00$16.00 to $11.17
Dorzox PF (Cipla)Dorzolamide, preservative free5 mL1 for $18.00; 3 for $44.00; 6 for $78.00$18.00 to $13.00
AzoptBrinzolamide 1%, carbonic anhydrase inhibitor5 mL1 for $32.00; 3 for $65.00; 6 for $118.00$32.00 to $19.67
CombiganBrimonidine 0.2% + timolol 0.5%5 mL1 for $18.00; 3 for $43.00; 6 for $86.00$18.00 to $14.33
Careprost Plus (Sun Pharma)Bimatoprost 0.03% + timolol 0.5%3 mL1 for $22.00; 3 for $60.00; 6 for $108.00$22.00 to $18.00
TravacomTravoprost + timolol2.5 mL1 for $37.00; 3 for $87.00; 6 for $156.00$37.00 to $26.00
Pilocar (FDC)Pilocarpine, miotic5 mL3 for $13.00; 6 for $25.00; 12 for $47.00$4.33 to $3.92

Per bottle figures are the pack price divided by the number of bottles, from the single bottle or smallest pack to the largest pack. Products containing timolol carry the asthma, COPD and heart contraindications described above. Cost and buying questions are covered in our guide to buying eye drops from an online pharmacy.

Buying glaucoma drops from outside the US

The FDA's personal importation page says: "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use because these products purchased from other countries often have not been approved by the FDA for use and sale in the U.S." It also says FDA staff "may consider a more permissive decision" in some situations, and that the agency "recommends only obtaining medicines from legal sources in the U.S." Read the FDA personal importation page and check the rules that apply to you before ordering. Our guide to buying eye care medicine online safely covers what to check on any pharmacy site.

Whatever you buy, glaucoma treatment depends on regular pressure checks. A drop can stop working well, or cause side effects you do not notice yourself, such as a slow pulse on timolol. Keep your eye doctor's follow up visits even when the eyes feel fine.

Sources

  1. American Academy of Ophthalmology. Primary Open-Angle Glaucoma Preferred Practice Pattern. Approved by the Board of Trustees 6 September 2025. Table 4 and medical treatment section. aao.org/ppp, PDF accessed 29 October 2026.
  2. van der Valk R, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177. PMID 15921747.
  3. American Academy of Ophthalmology. Color Codes for Topical Ocular Medications, policy revised June 2015. aao.org.
  4. American Academy of Ophthalmology EyeSmart. How to Put in Eye Drops. aao.org.
  5. Xalatan (latanoprost) US label, Viatris, DailyMed setid a98595b3-9f47-48e0-b18d-550a2095f264, October 2024.
  6. Lumigan 0.01% (bimatoprost) US label, Allergan, DailyMed setid a5e67c75-db88-4372-bb07-c8dd15c97631, July 2026.
  7. Travatan Z (travoprost) US label, Novartis, DailyMed setid 028455e0-ae77-4213-8819-3b58ef7d6a14, April 2026.
  8. Zioptan (tafluprost) US label, Thea, DailyMed setid db529b54-2ac7-4020-9791-7333bbe6c90f, May 2026.
  9. Vyzulta (latanoprostene bunod) US label, Bausch and Lomb, DailyMed setid 60ce7900-a677-4fc2-88d0-1603baa9dbd4, February 2024.
  10. Timoptic (timolol maleate) US label, Bausch and Lomb, DailyMed setid 45ac65b3-19f7-4f33-aebf-cadd3daa4bf1, September 2022.
  11. Betoptic S (betaxolol) US label, Novartis, DailyMed setid 905ba189-456c-4aa4-8231-39a971374ad8, January 2025.
  12. Alphagan P (brimonidine) US label, Allergan, DailyMed setid 264c4494-c225-486f-888a-caaf36be46b3, July 2026.
  13. Brimonidine tartrate 0.2% US label, Sandoz, DailyMed, 2025.
  14. Dorzolamide hydrochloride ophthalmic solution US label, Sandoz, DailyMed setid 29157995-fa61-4425-86a5-5bd0e4718cd8, October 2026.
  15. Azopt (brinzolamide) US label, Sandoz, DailyMed setid 0afb6589-51ba-432c-aed1-20a12d5d3455, October 2024.
  16. Rhopressa (netarsudil) US label, Alcon, DailyMed setid 7d4f0e3a-5b86-4c43-982a-813b22ae7e22, January 2026.
  17. Cosopt (dorzolamide and timolol) US label, Thea, DailyMed setid 23bdf1c1-3134-4ad1-8e7c-bc655156bdc6, April 2024.
  18. Combigan (brimonidine and timolol) US label, Allergan, DailyMed setid feaf1480-a4b8-4486-992a-96be3a596243, March 2026.
  19. Simbrinza (brinzolamide and brimonidine) US label, Alcon, DailyMed setid a49c157e-6310-0011-7b7f-e26fc1820d59, March 2025.
  20. Rocklatan (netarsudil and latanoprost) US label, Alcon, DailyMed setid b1d71f41-be06-4a08-94d4-e352198f09c2, September 2026.
  21. DuoTrav (travoprost and timolol) and Ganfort (bimatoprost and timolol), EU product information (sections 4.1 to 4.3), European Medicines Agency, accessed 29 October 2026.
  22. US Food and Drug Administration. Personal Importation. fda.gov, accessed 29 October 2026.

?Frequently Asked Questions

What are the main types of glaucoma eye drops?

There are six main types: prostaglandin analogs (latanoprost, bimatoprost, travoprost, tafluprost, latanoprostene bunod), beta blockers (timolol, betaxolol), alpha 2 agonists (brimonidine), carbonic anhydrase inhibitors (dorzolamide, brinzolamide), the rho kinase inhibitor netarsudil, and the miotic pilocarpine. Fixed combination bottles such as Cosopt, Combigan, Simbrinza and Rocklatan contain two of these.

Which glaucoma eye drop is usually prescribed first?

Usually a prostaglandin analog such as latanoprost. The AAO Primary Open-Angle Glaucoma Preferred Practice Pattern says prostaglandin analogs are the most frequently prescribed because they are most efficacious, well tolerated and used once daily, and are often selected first unless contraindications, cost, side effects, intolerance or patient refusal stand in the way. Selective laser trabeculoplasty is also supported as an initial treatment.

Which glaucoma eye drop lowers eye pressure the most?

In a meta-analysis of 28 randomized trials (van der Valk 2005), bimatoprost 0.03% lowered peak eye pressure by 33%, latanoprost and travoprost by 31%, and timolol by 27%, against 5% on placebo. The AAO guideline expects 25% to 33% from prostaglandin analogs, 20% to 25% from beta blockers and alpha agonists, 15% to 20% from carbonic anhydrase inhibitor drops and 10% to 20% from netarsudil.

Who should not use timolol eye drops?

The Timoptic label says timolol is contraindicated in bronchial asthma, a history of bronchial asthma, severe COPD, sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock, and hypersensitivity to any component. The same contraindications apply to combinations containing timolol, such as Cosopt and Combigan.

Can children use brimonidine eye drops?

Not under 2 years. The Alphagan P label states it is contraindicated in neonates and infants younger than 2, and reports apnea, bradycardia, coma, hypotension and respiratory depression in infants after marketing. In a study of children aged 2 to 7, somnolence occurred in 50% to 83% of those aged 2 to 6. Combigan and Simbrinza, which contain brimonidine, carry the same under 2 contraindication.

Can I use dorzolamide or brinzolamide if I am allergic to sulfa drugs?

Tell your eye doctor first. Both are sulfonamides, and their US labels warn that although used in the eye they are absorbed systemically, that rare fatal sulfonamide reactions such as Stevens-Johnson syndrome have occurred, and that the drop should be stopped if signs of serious reactions or hypersensitivity appear. The AAO guideline lists sulfonamide allergy as a potential contraindication for this class.

What do the cap colors on glaucoma eye drops mean?

In the US, the AAO color code assigns turquoise to prostaglandin analogues, yellow to beta blockers, dark blue to beta blocker combinations, purple to adrenergic agonists such as brimonidine, light green to adrenergic agonist combinations, orange to carbonic anhydrase inhibitors and dark green to miotics. Netarsudil is not in the list and its labels describe white caps. The system is voluntary and packs made for other countries may differ, so always read the drug name.

How long should I wait between two different glaucoma eye drops?

At least 5 minutes, according to most US labels and the AAO guideline. The Azopt label asks for at least 10 minutes between it and other drops, and the Betoptic S label says to give other drops at least 10 minutes before it. Waiting stops the second drop from washing out the first.

How do I put in glaucoma eye drops correctly?

Wash your hands, tilt your head back, pull the lower lid down to make a pocket and let one drop fall in without the tip touching the eye. Then close your eyes and press gently on the inner corner by the nose for a minute or two. The AAO says this keeps the drop in the eye and its glaucoma guideline says eyelid closure or nasolacrimal occlusion reduces systemic absorption.

What are the most common side effects of glaucoma eye drops?

It depends on the type. Prostaglandins cause red eyes, longer darker lashes and sometimes permanent darkening of the iris. Timolol causes stinging in about 1 in 8 people and can slow the heart or tighten the airways. Brimonidine causes allergic conjunctivitis and dry mouth. Dorzolamide causes stinging and a bitter taste. Netarsudil caused eye redness in 53% of patients in its label trials.

Are combination glaucoma eye drops better than two separate drops?

They are simpler, not stronger. The Cosopt, Combigan, Simbrinza and Rocklatan labels show the combination lowered pressure about 1 to 3 mmHg more than either drug alone, but Cosopt and Combigan lowered it about 1 to 2 mmHg less than the two drugs given separately at full dosing. The AAO guideline says combinations may help adherence but are not recommended for initial treatment in most circumstances.

S

SafeRxPills Pharmacy Team

Pharmacist, Content, B.Pharm, M.Pharm, Rajiv Gandhi University

Pharmacist writing on antiparasitic, ophthalmic and dermatological generics. Focuses on what the regulatory labelling and published evidence actually support.

Comments (0)

Leave a Comment

No comments yet. Be the first to share your thoughts!